Portal de Periódicos da CAPES

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

2024; Adis, Springer Healthcare; Volume: 13; Issue: 11 Linguagem: Inglês

10.1007/s40123-024-01036-4

2193-6528

Giuseppe Cancian, A. Paris, Lia Agliati, Angelica Rizzato, Michele Clerici, Giulio Volpe, Moreno Menghini, Gabriela Grimaldi,

Retinal and Optic Conditions

This study assessed the efficacy, durability, and safety of faricimab in patients with neovascular age-related macular degeneration (nAMD), previously treated with aflibercept or ranibizumab with unsatisfactory results.